$NRX.V Outpaces Biotech Peers Following TSX.V Listing
The biotech sector is presenting exciting opportunities for investors despite the broader downturn in global equity markets. Many of the best biotech companies and ETFs have both strong drug candidate pipelines in the works as well as winning drugs and therapeutic products already on the market. The COVID-19 pandemic has proven and created massive opportunities for the biotechnology sector as a whole, particularly so around innovative players that are developing therapeutic solutions with disruptive potential.
One new player to the field is Nurexone Biologic (NRX.V), a new listee on the TSXV exchange that is redefining exosome therapeutics for application to traumatic brain and spinal cord injuries. It is creating a platform for biologically-guided ExoTherapy that will be administered minimally invasively to patients who have had catastrophic spinal cord injuries.
Since July 15th, NRX +26% as it attracts new investors and institutional players begin to trade the equity. In comparison, the TSX/SPX composite index charted 6% gains, indicating that NRX far outperformed the market baseline over the course of the summer rally. Relative to sectoral ETFs, Nurexone is also trading strong. IBBQ is +6.9% and XBI +6% over the same timeframe NRX is +26%; it is important to note that over this period, the company did not release any price sensitive announcements that would otherwise account for its significant bullish price movement.
Further, exosome-based equities are one area of the wider biotech industry that has continuously traded robustly despite subpar performance for equity markets this year. Sectoral competitors are mixed bag, with KMPH +4.8% while APTO is down 4.4%. Kodiak Biosciences (KOD) jumped 20%, though it still lags behind NRX's 26% increase. This indicates that as exosome therapeutic developers struggle to maintain forward momentum amidst the backdrop of a challenging macroeconomic landscape, NRX is outperforming both sectoral ETFs and direct competitors. Though its a newby to capital markets, so far Nurexone is standing out as the bullish outlier with LT potential.
One new player to the field is Nurexone Biologic (NRX.V), a new listee on the TSXV exchange that is redefining exosome therapeutics for application to traumatic brain and spinal cord injuries. It is creating a platform for biologically-guided ExoTherapy that will be administered minimally invasively to patients who have had catastrophic spinal cord injuries.
Since July 15th, NRX +26% as it attracts new investors and institutional players begin to trade the equity. In comparison, the TSX/SPX composite index charted 6% gains, indicating that NRX far outperformed the market baseline over the course of the summer rally. Relative to sectoral ETFs, Nurexone is also trading strong. IBBQ is +6.9% and XBI +6% over the same timeframe NRX is +26%; it is important to note that over this period, the company did not release any price sensitive announcements that would otherwise account for its significant bullish price movement.
Further, exosome-based equities are one area of the wider biotech industry that has continuously traded robustly despite subpar performance for equity markets this year. Sectoral competitors are mixed bag, with KMPH +4.8% while APTO is down 4.4%. Kodiak Biosciences (KOD) jumped 20%, though it still lags behind NRX's 26% increase. This indicates that as exosome therapeutic developers struggle to maintain forward momentum amidst the backdrop of a challenging macroeconomic landscape, NRX is outperforming both sectoral ETFs and direct competitors. Though its a newby to capital markets, so far Nurexone is standing out as the bullish outlier with LT potential.